AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Cardiac Allograft Vasculopathy, Heart Transplant
In brief
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
Key facts
- Study ID
- NCT04770012
- Run by
- Ottawa Heart Institute Research Corporation
- People needed
- 135
- Starts
- 2021-06-28
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-05-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Heart transplant
- Age ≥18 years
- Able to provide informed consent
You may not qualify if…
- Allergy or known intolerance to aspirin
- Allergy or known intolerance to clopidogrel
- Intracranial hemorrhage ≤14 days
- Bleeding disorder
- Platelet count <50 x 109/L
- History of aspirin related gastrointestinal bleeding or ulcers
- Non-cardiac indication for antiplatelet therapy
- Anticoagulation >3 months
- Allergy to iodinated contrast
- Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL/min/1.73 m2 for non-dialysis patients
- Unable to undergo coronary angiography due to unsuitable vascular access
- Combined solid organ transplantation.
Where it is running
- St.Pauls Hospital — Vancouver, British Columbia, Canada (enrolling)
- University of Ottawa Heart Institute — Ottawa, Ontario, Canada (enrolling)
- Toronto General Hospital UHN — Toronto, Ontario, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.